Concepedia

Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40‐week extension of the GUARD randomized study

Sang Youb Han, Sun Ae Yoon, Byoung Geun Han, Sung Gyun Kim, Young‐Il Jo, Kyung Hwan Jeong, Kook‐Hwan Oh, Hyeong Cheon Park, Sun‐Hee Park, Shin‐Wook Kang,

Diabetes Obesity and Metabolism · 2017 · 14 citations · 20 references

DOIFull text

Open access

Abstract

Gemigliptin and linagliptin did not differ with respect to safety and efficacy in patients with T2DM and renal impairment. The 2 drugs had similar glucose-lowering effects, and the changes in eGFR and albuminuria were also similar. Additionally, the risk of side effects, including hypoglycaemia, was similar between the 2 groups.

References

20

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

American Journal of Kidney Diseases · 2012 · 1.3K citations

, , +6

Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction

Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic et al. · Diabetes Care · 2013 · 295 citations · Full text

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Ofri Mosenzon, Gil Leibowitz, Deepak L. Bhatt et al. · Diabetes Care · 2016 · 267 citations

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

Juliana C.N. Chan, Russell Scott, Juan Camilo Arjona Ferreira et al. · Diabetes Obesity and Metabolism · 2008 · 238 citations

Long-Term Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes and Severe Renal Impairment

Janet B. McGill, Lance Alan Sloan, Jennifer Newman et al. · Diabetes Care · 2012 · 203 citations · Full text